| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1056/NEJMRA040226 |
| P698 | PubMed publication ID | 15201416 |
| P2093 | author name string | James R O'Dell | |
| P433 | issue | 25 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 2591-2602 | |
| P577 | publication date | 2004-06-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Therapeutic strategies for rheumatoid arthritis | |
| P478 | volume | 350 |
| Q88757204 | 18F- FDG PET/CT joint assessment of early therapeutic response in rheumatoid arthritis patients treated with rituximab |
| Q33902773 | A Haystack Heuristic for Autoimmune Disease Biomarker Discovery Using Next-Gen Immune Repertoire Sequencing Data |
| Q35240630 | A multicenter clinical trial in rheumatoid arthritis comparing silicone metacarpophalangeal joint arthroplasty with medical treatment |
| Q81568703 | A pilot study of acupuncture as adjunctive treatment of rheumatoid arthritis |
| Q35907809 | Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis |
| Q37213189 | Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis |
| Q36288599 | Advances in the treatment of inflammatory arthritis |
| Q27691822 | Advances in the treatment of rheumatoid arthritis. |
| Q33765844 | Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study. |
| Q38437371 | Albumin-Oxanorbornadiene Conjugates Formed ex Vivo for the Extended Circulation of Hydrophilic Cargo |
| Q43061720 | Anakinra in the treatment of rheumatic disease |
| Q93234922 | Anti-Arthritic Effect of Garcinol Enriched Fraction Against Adjuvant Induced Arthritis |
| Q24816803 | Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis |
| Q35228585 | Anti-arthritic activity of Fu-Fang-Lu-Jiao-Shuang on collagen-induced arthritis in Balb/c mice and its underlying mechanisms |
| Q35836496 | Anti-inflammatory effects of polyphenolic-enriched red raspberry extract in an antigen-induced arthritis rat model |
| Q35165677 | Are rheumatologists' treatment decisions influenced by patients' age? |
| Q64293832 | Au Clusters Treat Rheumatoid Arthritis with Uniquely Reversing Cartilage/Bone Destruction |
| Q35555021 | Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis |
| Q34369278 | Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses |
| Q37631869 | Beyond oncology--application of HPMA copolymers in non-cancerous diseases. |
| Q35579491 | Biological drug use: US perspectives on indications and monitoring |
| Q37104074 | Biomechanical strain regulates TNFR2 but not TNFR1 in TMJ cells |
| Q34822708 | Blocking interleukin-1 in rheumatic diseases |
| Q37270792 | Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis |
| Q45877777 | Bone-protective effects of nonviral gene therapy with folate-chitosan DNA nanoparticle containing interleukin-1 receptor antagonist gene in rats with adjuvant-induced arthritis |
| Q38274571 | Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis |
| Q90999599 | Chloroquine modulates inflammatory autoimmune responses through Nurr1 in autoimmune diseases |
| Q48148502 | Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis. |
| Q33333034 | Classification of rheumatoid arthritis status with candidate gene and genome-wide single-nucleotide polymorphisms using random forests |
| Q34124686 | Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial |
| Q33893960 | Correlation of anti-cyclic citrullinated antibody with hand joint erosion score in rheumatoid arthritis patients |
| Q57557905 | Design, synthesis and evaluation of ()-3-(7-(methyl(7-pyrrolo[2,3-]pyrimidin-4-yl)amino)-5-azaspiro[2.4]heptan-5-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor |
| Q37774824 | Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis |
| Q36699052 | Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs--from bench to bedside |
| Q79356042 | Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis |
| Q37144969 | Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health States. |
| Q37230822 | Effects of nitric oxide on neutrophil influx depends on the tissue: role of leukotriene B4 and adhesion molecules |
| Q36246592 | Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs |
| Q92213919 | Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3) |
| Q92213914 | Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan |
| Q24658506 | Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study |
| Q39304368 | Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial |
| Q37210207 | Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study |
| Q35054330 | Efficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti-rheumatic drugs: a meta-analysis of randomized double-blind controlled studies |
| Q36406242 | Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists |
| Q41550801 | Extended blood circulation and joint accumulation of a p(HPMA-co-AzMA)-based nanoconjugate in a murine model of rheumatoid arthritis. |
| Q55514601 | Fabrication of a triptolide-loaded and poly-γ-glutamic acid-based amphiphilic nanoparticle for the treatment of rheumatoid arthritis. |
| Q24312144 | Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients |
| Q36465487 | Gait analysis in a murine model of collagen-induced arthritis |
| Q37498849 | Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis |
| Q35247643 | Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis |
| Q54647088 | Healing the Syk through Kinase Inhibitors |
| Q34749585 | Hepatitis B virus (HBV) and autoimmune disease |
| Q40382073 | Herb Network Analysis for a Famous TCM Doctor's Prescriptions on Treatment of Rheumatoid Arthritis |
| Q61451717 | Hyaluronic Acid Coated Acid-Sensitive Nanoparticles for Targeted Therapy of Adjuvant-Induced Arthritis in Rats |
| Q37208955 | Immunomodulatory approaches to the management of chronic urticaria: an immune-mediated inflammatory disease |
| Q37531008 | Improved survival in rheumatoid arthritis: a general population-based cohort study |
| Q36245714 | Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity |
| Q85724508 | Inhibitory effect of anethole in nonimmune acute inflammation |
| Q84504239 | Inhibitory effect of the antimalarial agent artesunate on collagen-induced arthritis in rats through nuclear factor kappa B and mitogen-activated protein kinase signaling pathway |
| Q36204088 | Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial) |
| Q34758283 | Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis. |
| Q40340532 | Intravenous application of omega-3 fatty acids in patients with active rheumatoid arthritis. The ORA-1 trial. An open pilot study |
| Q36789768 | Intravenous pamidronate for refractory rheumatoid arthritis |
| Q34562870 | Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study |
| Q37084924 | Long-term exposure to PGE2 causes homologous desensitization of receptor-mediated activation of protein kinase A. |
| Q46475191 | Low-dose methotrexate treatment for oligoarticular juvenile idiopathic arthritis nonresponsive to intra-articular corticosteroids |
| Q36417085 | MDR-1 and MRP-1 activity in peripheral blood leukocytes of rheumatoid arthritis patients |
| Q34641300 | Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology |
| Q36588856 | Medical therapy: where are we now? |
| Q30483827 | N-of-1 trials of expensive biological therapies: a third way? |
| Q48336970 | Neutrophils-derived peroxynitrite contributes to acute hyperalgesia and cell influx in zymosan arthritis. |
| Q35769042 | Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis. |
| Q34559803 | Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs? |
| Q34027551 | Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis |
| Q46125639 | Oral GABA treatment downregulates inflammatory responses in a mouse model of rheumatoid arthritis |
| Q91793948 | Oral administration of alpha-lipoic acid did not affect lipid peroxidation and antioxidant biomarkers in rheumatoid arthritis patients |
| Q39799883 | Organising pneumonia as the first manifestation of rheumatoid arthritis |
| Q46217168 | PS3, a semisynthetic beta-1,3-glucan sulfate, diminishes contact hypersensitivity responses through inhibition of L- and P-selectin functions. |
| Q92638674 | Patterns of health care utilization of gout patients in Hawai'i-high rates of emergency department utilization as compared to rheumatoid arthritis |
| Q40264431 | Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-hydroxypropyl)methacrylamide copolymers |
| Q37502434 | Predicting and verifying outcome of Tripterygium wilfordii Hook F. based therapy in rheumatoid arthritis: from open to double-blinded randomized trial |
| Q37372556 | Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. |
| Q43591934 | Preliminary study on the immunologic background of good clinical outcome in rheumatoid arthritis patients after one month therapy with leflunomide. |
| Q33503888 | Protective effect of geranylgeranylacetone, an inducer of heat shock protein 70, against drug-induced lung injury/fibrosis in an animal model |
| Q37067664 | Protective efficacy of N-(2-hydroxyphenyl) acetamide against adjuvant-induced arthritis in rats |
| Q30481543 | Protocol for the combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) trial: a multi-centre, double-masked, factorial randomised controlled trial |
| Q35098842 | Randomised double-blind trial of combination antibiotic therapy in rheumatoid arthritis |
| Q28575086 | Regulation of matrix metalloproteinase expression by dynamic tensile strain in rat fibrochondrocytes |
| Q24817151 | Reliability of computerized image analysis for the evaluation of serial synovial biopsies in randomized controlled trials in rheumatoid arthritis |
| Q36392370 | Remission by composite scores in rheumatoid arthritis: are ankles and feet important? |
| Q40748158 | Rheumatoid lung |
| Q21131938 | Role of key TYMS polymorphisms on methotrexate therapeutic outcome in portuguese rheumatoid arthritis patients |
| Q90275260 | Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan |
| Q34420356 | Selective delivery of interleukine-1 receptor antagonist to inflamed joint by albumin fusion |
| Q36531030 | Serum levels of 14-3-3η protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis |
| Q36453573 | Short time administration of antirheumatic drugs - methotrexate as a strong inhibitor of osteoblast's proliferation in vitro |
| Q46173041 | Single center prospective study of tacrolimus efficacy and safety in treatment of rheumatoid arthritis |
| Q37813491 | Sphingosine-1-phosphate: a potential therapeutic target for rheumatoid arthritis |
| Q40176569 | Sulfasalazine sensitises human monocytic/macrophage cells for glucocorticoids by upregulation of glucocorticoid receptor alpha and glucocorticoid induced apoptosis |
| Q36994094 | Synthesis and evaluation of a well-defined HPMA copolymer-dexamethasone conjugate for effective treatment of rheumatoid arthritis |
| Q36801049 | The Development of Novel Therapies for Rheumatoid Arthritis |
| Q53860668 | The case of tumour necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis: a budget impact analysis. |
| Q81710045 | The comparative effectiveness of methotrexate and anti-tumor necrosis factor therapy in psoriatic arthritis |
| Q24648473 | The endocannabinoid system as an emerging target of pharmacotherapy |
| Q39062334 | The histone deacetylase inhibitors MS-275 and SAHA suppress the p38 mitogen-activated protein kinase signaling pathway and chemotaxis in rheumatoid arthritic synovial fibroblastic E11 cells. |
| Q48852744 | The immunomodulatory properties of human bone marrow-derived mesenchymal stromal cells are defined according to multiple immunobiological criteria |
| Q36845302 | The interleukin-17 receptor plays a gender-dependent role in host protection against Porphyromonas gingivalis-induced periodontal bone loss |
| Q51476013 | The metabolic changes caused by dexamethasone in the adjuvant-induced arthritic rat. |
| Q43634290 | The relationship between quality of life and aerobic fitness in patients with rheumatoid arthritis |
| Q41996003 | The snake venom metalloproteinase BaP1 induces joint hypernociception through TNF-alpha and PGE2-dependent mechanisms |
| Q56060521 | Treatment of rheumatoid arthritis |
| Q35285239 | Validity and responsiveness of the Michigan Hand Questionnaire in patients with rheumatoid arthritis: a multicenter, international study |
| Q84018462 | Very recent onset arthritis: the value of initial rheumatologist evaluation and anti-cyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis |
| Q33566367 | Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? |
| Q81345914 | [Anti IgE antibodies for the treatment of difficult asthma] |
| Q79759480 | [Cooperation between primary care physicians and rheumatologists in Lower Saxony. Results of a survey of primary care physicians] |
| Q51199883 | [How early would we really administer biologics?]. |
| Q84600331 | [Reduction in time until first treatment with disease modifying treatment in patients with rheumatoid arthritis] |
| Q52895477 | [Therapeutic strategies in rheumatoid arthritis]. |
Search more.